Drugs by condition
Drugs approved for brain tumors (glioma)
Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
18
Still marketed, NDA or BLA
Drug classes
5
Novel drugs
8
New molecular entities and new biologics
In development
40+
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for brain tumors (glioma).
- Pixclara (Floretyrosine F-18) · Telix NovelPriority reviewOrphanSep 11, 2026
- Modeyso (Dordaviprone Hydrochloride) · Chimerix NovelAccelerated approvalPriority reviewOrphanAug 6, 2025
- Jobevne (Bevacizumab-Nwgd) · Biocon Biologics INC Apr 9, 2025
- Ojemda (Tovorafenib) · Day One Biopharms NovelAccelerated approvalPriority reviewOrphanApr 23, 2024
- Ojemda (Tovorafenib) · Day One Biopharms NovelAccelerated approvalPriority reviewOrphanApr 23, 2024
All approved drugs for brain tumors (glioma), by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 16 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Vascular Endothelial Growth Factor Inhibitor (6)
Kinase Inhibitor (2)
Alkylating Drug (2)
Protease Activator (1)
- Modeyso Dordaviprone Hydrochloride · Chimerix · 2025
Class not listed in FDA's data (7)
- Pixclara Floretyrosine F-18 · Telix · 2026
- Tafinlar Dabrafenib Mesylate · Novartis · 2013
- Mekinist Trametinib Dimethyl Sulfoxide · Novartis · 2013
- Bicnu Carmustine · Avet Lifesciences · 1977
- Mekinist Trametinib, Trametinib Dimethyl Sulfoxide · Novartis · 2023
- Tafinlar Dabrafenib Mesylate · Novartis · 2023
- Gleolan Aminolevulinic Acid Hydrochloride · Nxdc · 2017
Drugs in development for brain tumors (glioma)
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- Anlotinib hydrochlorideAL3818, CatequentenibPhase 312 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Alveolar Soft Part Sarcoma, Metastatic Colorectal Cancer, Endometrial Neoplasms
- L19TNFL19IL2, OnfekafuspPhase 310 trials
Philogen S.p.A. · Glioblastoma, Locally Advanced Basal Cell Carcinoma, Melanoma Stage III
- VebreltinibPLB1001Phase 36 trials
Avistone Biotechnology Co., Ltd. · Non-Small-Cell Lung Cancer, Glioblastoma, Non-Small Cell Lung Cancer
- luvometinibFCN-159Phase 34 trials
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Non-small Cell Lung Caner, KRAS-mutated, Metastasis
- SafusidenibDS-1001b, AB-218Phase 34 trials
Nuvation Bio Inc. · Oligodendroglioma, Glioma, IDH1-mutant Glioma
- APG-157Phase 33 trials
Aveta Biomics, Inc. · Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity, Squamous Cell Carcinoma of the Oropharynx
- pegargiminaseADI-PEG 20Phase 33 trials
Polaris Group · Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma
- VRT106Phase 33 trials
Guangzhou Virotech Pharmaceutical Co., Ltd. · Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma, HCC
- CobolimabPhase 32 trials
GSK · Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma
- JK-1201IPhase 32 trials
JenKem Technology Co., Ltd. · Glioblastoma Multiforme (GBM), Small Cell Lung Cancer
- LAM561Phase 32 trials
Laminar Pharmaceuticals · Primary Glioblastoma, Glioblastoma Multiforme, High-grade Glioma
- INO-9012Phase 24 trials
Geneos Therapeutics · HCC, Glioblastoma, Urothelial Carcinoma
- AL58805Phase 22 trials
Advenchen Pharmaceuticals, LLC. · Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms
- AzeliragonPhase 22 trials
Cantex Pharmaceuticals · Glioblastoma
- BreakVaxPhase 22 trials
BreakBio Corp · Triple-Negative Breast Cancer (TNBC), Glioblastoma (GBM)
- DOC1021Phase 22 trials
Diakonos Oncology Corporation · Glioblastoma (GBM), Refractory Melanoma
- Fianlimab [Fixed ]Phase 22 trials
Regeneron · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- INO-5401Phase 22 trials
Inovio Pharmaceuticals · Glioblastoma, Urothelial Carcinoma
- Intracerebroventricular of MT027 UCAR-T Cell targeting B7H3Phase 22 trials
T-MAXIMUM Pharmaceutical Inc · Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Brain Metastases From Solid Tumors
- MT-125Phase 22 trials
Myosin Therapeutics Inc. · Glioblastoma (GBM), Glioblastoma
1 discontinued brand-name drugs whose label still names it
- Temodar Temozolomide
More on brain tumors (glioma): recruiting trials · published research
Related in oncology: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Prostate cancer · Colorectal cancer · Melanoma · Ovarian cancer · Pancreatic cancer · Bladder and urothelial cancer · Kidney cancer (renal cell carcinoma)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.